Letter to Editor: 'Identification of patients with favorable prognosis after resection in intermediate-stage hepatocellular carcinoma'.
作者信息
Xu You-Jian, Pang Hui-Ming
机构信息
Department of General Surgery, Tiantai People's Hospital of Zhejiang Province (Tiantai Branch of Zhejiang Provincial People's Hospital), Hangzhou Medical College, Taizhou, Zhejiang, People's Republic of China.
出版信息
Int J Surg. 2024 Sep 1;110(9):5916-5917. doi: 10.1097/JS9.0000000000001681.
Abstract
摘要
相似文献
1
Letter to Editor: 'Identification of patients with favorable prognosis after resection in intermediate-stage hepatocellular carcinoma'.致编辑的信：“中期肝细胞癌切除术后预后良好患者的识别”
Int J Surg. 2024 Sep 1;110(9):5916-5917. doi: 10.1097/JS9.0000000000001681.
2
Letter to the editor: 'A simple scoring system to predict early recurrence after surgical resection for hepatocellular carcinoma'.
Liver Int. 2024 Sep;44(9):2498-2499. doi: 10.1111/liv.15968. Epub 2024 Jul 16.
3
Response to LTE regarding-Importance of tumor size as a prognostic factor after partial liver resection for solitary hepatocellular carcinoma: Implications on the current AJCC staging system.
J Surg Oncol. 2016 Apr;113(5):594. doi: 10.1002/jso.24172.
4
[Curative therapy of hepatocellular carcinoma (HCC). Resection or transplantation?].[肝细胞癌（HCC）的根治性治疗。手术切除还是肝移植？]
Internist (Berl). 2000 Feb;41(2 Pt 2):191-7. doi: 10.1007/s001080050024.
5
Letter to editor: Does age effect on the short- and long-term outcomes of patients undergoing liver resection for hepatocellular carcinoma?
Eur J Surg Oncol. 2022 Apr;48(4):933-934. doi: 10.1016/j.ejso.2022.01.006. Epub 2022 Jan 7.
6
Reply to the Letter to the Editor: Oncological benefit of anatomic resection for patients with hepatocellular carcinoma.致编辑的信的回复：肝细胞癌患者解剖性切除的肿瘤学获益
Surg Today. 2023 Oct;53(10):1217. doi: 10.1007/s00595-023-02735-4. Epub 2023 Aug 14.
7
[Arguments for surgical resection of hepatocellular carcinoma greater than 20 cm].
Ann Chir. 2002 May;127(5):402-3. doi: 10.1016/s0003-3944(02)00780-0.
8
Thrombocytopenia predicts the prognosis of hepatocellular carcinoma patients with Ishak score 6 after hepatectomy: A propensity score matching analysis.血小板减少症可预测肝切除术后Ishak评分为6分的肝细胞癌患者的预后：一项倾向评分匹配分析。
Asian J Surg. 2021 Jan;44(1):423-424. doi: 10.1016/j.asjsur.2020.10.027. Epub 2020 Nov 25.
9
[A survival analysis of patients with early-stage hepatocellular carcinoma fulfilling Milan criteria and undergoing hepatectomy].[对符合米兰标准并接受肝切除术的早期肝细胞癌患者的生存分析]
Zhonghua Yi Xue Za Zhi. 2010 Dec 14;90(46):3251-4.
10
Is liver transplantation superior to resection in early stage hepatocellular carcinoma?
Transplant Proc. 1999 Feb-Mar;31(1-2):500-1. doi: 10.1016/s0041-1345(98)01727-8.
本文引用的文献
1
PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.异常凝血酶原（PIVKA-II）联合肿瘤负荷评分预测 AFP 阴性肝癌患者肝切除术后的长期预后。
Cancer Med. 2024 Jan;13(1):e6835. doi: 10.1002/cam4.6835. Epub 2023 Dec 21.
2
Identification of patients with favorable prognosis after resection in intermediate-stage-hepatocellular carcinoma.识别中危期肝细胞癌切除术后预后良好的患者。
Int J Surg. 2024 Feb 1;110(2):1008-1018. doi: 10.1097/JS9.0000000000000941.
3
Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection.替诺福韦与恩替卡韦在 HBV 相关 HCC 切除术后患者中的应用。
JAMA Netw Open. 2023 Oct 2;6(10):e2340353. doi: 10.1001/jamanetworkopen.2023.40353.
4
Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: A propensity score matching analysis.新辅助载药微球经动脉化疗栓塞联合替雷利珠单抗治疗可切除或边界可切除肝细胞癌：倾向评分匹配分析。
Eur J Surg Oncol. 2023 Dec;49(12):107106. doi: 10.1016/j.ejso.2023.107106. Epub 2023 Sep 30.
5
The Tumor Burden Score: A New "Metro-ticket" Prognostic Tool For Colorectal Liver Metastases Based on Tumor Size and Number of Tumors.肿瘤负荷评分：一种基于肿瘤大小和肿瘤数量的用于结直肠癌肝转移的新型“地铁票”预后工具。
Ann Surg. 2018 Jan;267(1):132-141. doi: 10.1097/SLA.0000000000002064.
Zotero 插件